---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-21-021383"
form_type: "8-K"
ticker: "INBP"
cik: "0001016504"
company_name: "INTEGRATED BIOPHARMA INC"
filed_at: "2021-09-02T23:59:59+00:00"
generated_at: "2026-06-29T05:58:28.086921+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Integrated BioPharma reports FY net income $8.0M, revenue up 20.5% YoY

## Summary
- Revenue for FY ended June 30, 2021: $63.6M, up 20.5% YoY from $52.8M.
- FY net income $8.0M ($0.27 basic EPS) vs $4.1M ($0.14 basic EPS) prior year.
- Q4 revenue $17.1M (+26.7% YoY); Q4 net income $4.5M ($0.15 basic EPS) vs $1.9M ($0.06).
- FY operating income $5.8M vs $3.3M prior year; PPP forgiveness of $1.7M boosted other income.
- Two customers represent ~92% of total revenue in both FY2021 and FY2020, per co-CEOs.

## SEC filing metadata
- accession: 0001437749-21-021383
- form_type: 8-K
- ticker: INBP
- cik: 0001016504
- company_name: INTEGRATED BIOPHARMA INC
- filed_at: 2021-09-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1016504/000143774921021383/0001437749-21-021383-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1016504/000143774921021383/inbp20210902_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-21-021383
- JSON: https://secwatch.observer/filing/0001437749-21-021383.json
- Plain text: https://secwatch.observer/filing/0001437749-21-021383.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.